Yüklüyor......
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
OBJECTIVES: Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration‐dependent neuroprotective effects in animal models of Parkinson’s disease (PD) but failed to show efficacy in a phase 3 clinical trial. The objectives of this study were to model the plasma phar...
Kaydedildi:
| Yayımlandı: | Ann Clin Transl Neurol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7951102/ https://ncbi.nlm.nih.gov/pubmed/33460320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51300 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|